Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abrams P, Cardozo L, Fall M, Grififiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standarisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff JW, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766
Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48:5–26
Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol 43:1–5
de Groat WC (2004) The urothelium in overactive bladder: passive bystander or active participant? Urology 64(6 Suppl 1):7–11
Hawthorn MH, Chapple CR, Cock M, Chess-Williams R (2000) Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129:416–419
Yoshida M, Inadome A, Murakami S, Otani M, Miyamae K, Iwashita H et al (2003) Effects of age and bladder stretching on non-neurogenic acetylcholine release from human bladder. J Urol 169:316
Michel MC, Hegde SS (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists—a matter of metabolites? Arch Pharmacol 374:79–85
Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Intl 97:400–403
Guay DRP (2003) Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 42:1243–1285
Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E (2005) Muscarinic receptors subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144:1089–1099
Chai TC, Sun Y (2006) Augmented extracellular ATP signaling in bladder urothelium cells from patients with interstitial cystitis. Am J Physiol Cell Physiol 290:C27–34
Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238–242
Iijima K, De Wachter S, Wyndaele JJ (2007) Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52:842–847
Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98:503–507
Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J (2005) for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470